INNOCARE(SH:688428) Globenewswire·2026-02-13 02:21Core Viewpoint - InnoCare Pharma has initiated the Phase II/III clinical trial for its TYK2 inhibitor soficitinib, targeting chronic spontaneous urticaria (CSU), while also advancing trials for other autoimmune conditions [1][2]. Group 1: Clinical Trials and Development - The first patient has been dosed in the Phase II/III clinical trial of soficitinib for CSU [1]. - Patient enrollment is complete for the Phase III trial of soficitinib for moderate to severe atopic dermatitis and the Phase II trial for vitiligo [2]. - Clinical trials for soficitinib are also underway for psoriasis and nodular prurigo [2]. Group 2: Mechanism and Indications - Soficitinib is a selective TYK2 inhibitor aimed at treating T-cell related autoimmune disorders, with a focus on dermatological applications [3]. - The drug works by blocking signaling pathways related to cytokines that cause mast cell activation and inflammation, thereby alleviating symptoms of CSU [4]. Group 3: Market Potential and Patient Demographics - CSU affects approximately 50 million patients globally, with the treatment market projected to reach $3 billion by 2029 [6]. - The condition is characterized by recurrent wheals and itching, often lasting two to five years, necessitating long-term treatment strategies [5]. Group 4: Company Overview - InnoCare is a biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with operations in multiple cities in China and the United States [6].